News About: Pharm. Affairs
Attacks of follow-up ezetimibe-statin products, leading 50% market growth
Follow-up products which entered the market after the patent expiration of ezetimibe, a hyperlipidemia therapy, last April, have quickly started to make performances.
Due the effect of the follow-up products, the eze...
Domestic pharmaceutical-biopharmaceutical companies concludes technology exports of USD 600 million in half year
Domestic pharmaceutical and biopharmaceutical companies’ results in R&D have been drawn out. Just like the last year, they showed results in global technology exports this year.
According to HI Investment & Securitie...
This year’s cosmetics exports expected to reach KRW 4 trillion
This year’s cosmetics exports were expected to reach KRW 4 trillion(USD 3.5 billion). Moreover, the exports were observed to be increased approximately 3.2 times up for the past 5 years.
According to the ‘2015 Export...
One thing after another, SK Chemicals’ journey to overcome Prevenar 13 patents
Although SK Chemicals is about to commercialized its first 13-valent pneumococcal vaccine for the first time in Korea, it seems it will take more time to sell it in the market.
This is because it has to overcome the ...
Foreign rare disease treatments start to enter Korea
It was confirmed foreign drug companies’ rare disease therapies or substances that are unknown to Korea were prepared to have clinical trials in Korea. It seems the movement has been led by the growth of the rare dise...
Remsima acquires IBD indication in Canada, accelerating expansion into NA market
Celltrion announced it acquired an addition indication of inflammatory bowel disease(IBD) for its autoimmune disease therapy, antibody biosimilar ‘Remsima(local name: Inflectra)’ from the Health Canada on June 10(loca...
Humira’s PMS ends on August, triggering biosimilar development competition
The domestic PMS(post marketing surveillance) of Humira(adalimumab, Abbvie), a rheumatoid arthritis treatment having the globally KRW 16 trillion sales market, will end this August.
Since the development of Humira b...
Why did domestic companies join in ADA to announce their new antidiabetics?
With study results of antidiabetics that are being developed with foreign pharmaceutical companies, domestic companies started to knock the door of the American Diabetes Association(ADA).
Domestic new drugs represent...
Physicians’ opposition even with extension of indications on ‘Daklinza’
Medical personnel have expressed opposition to the fact that the indication for genotype 2 was excluded from ‘Daklinza(generic name: daclatasvir)’ during the process of extending indications.
Recently, the Ministry o...
Cervical cancer vaccines for NIP, successfully bid on SK Chemicals and Boryung
The tenders for cervical cancer vaccines which will be included in the NIP from this month were settled.
Based on the result of the Public Procurement Service’s re-tenders for cervical cancer vaccines, the Korea Cent...
